Northwest Capital Management Inc Reduces Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Northwest Capital Management Inc cut its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 9.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 972 shares of the biotechnology company’s stock after selling 100 shares during the period. Northwest Capital Management Inc’s holdings in Axon Enterprise were worth $388,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Quent Capital LLC grew its position in Axon Enterprise by 1,875.0% in the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 75 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 79 shares during the period. Trivant Custom Portfolio Group LLC bought a new stake in shares of Axon Enterprise in the first quarter valued at about $31,000. First PREMIER Bank purchased a new stake in Axon Enterprise in the first quarter worth about $33,000. Finally, Rise Advisors LLC grew its holdings in Axon Enterprise by 49.0% during the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 47 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AXON. Barclays lifted their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Craig Hallum increased their price objective on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Robert W. Baird boosted their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. JMP Securities increased their price target on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, Jefferies Financial Group initiated coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $426.99 on Wednesday. The firm’s fifty day moving average is $370.34 and its two-hundred day moving average is $325.13. The firm has a market cap of $32.27 billion, a price-to-earnings ratio of 124.85, a PEG ratio of 11.30 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. Axon Enterprise, Inc. has a one year low of $199.29 and a one year high of $433.48.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company’s revenue was up 34.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.80 earnings per share. Research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Insider Transactions at Axon Enterprise

In related news, Director Jeri Williams sold 110 shares of the stock in a transaction on Monday, September 30th. The shares were sold at an average price of $400.00, for a total transaction of $44,000.00. Following the sale, the director now directly owns 1,934 shares of the company’s stock, valued at approximately $773,600. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Axon Enterprise news, CEO Patrick W. Smith sold 4,767 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $404.14, for a total value of $1,926,535.38. Following the sale, the chief executive officer now directly owns 2,925,060 shares of the company’s stock, valued at approximately $1,182,133,748.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeri Williams sold 110 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $400.00, for a total value of $44,000.00. Following the transaction, the director now directly owns 1,934 shares of the company’s stock, valued at approximately $773,600. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 370,172 shares of company stock valued at $136,562,182 in the last 90 days. 6.10% of the stock is currently owned by company insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.